Iwata, Hiroji and Masuda, Norikazu and Kim, Sung-Bae and Inoue, Kenichi and Rai, Yoshiaki and Fujita, Takashi and Chiu, Joanne and Ohtani, Shoichiro and Takahashi, Masato and Miyaki, Toshiko and Lu, Yen-Shen and Xu, Binghe and Yap, Yoon Sim and Bustam, Anita Zarina and Yao, Bin and Zhang, Bo and Bryce, Richard and Chan, Arlene (2019) Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Future Oncology, 15 (21). pp. 2489-2501. ISSN 1479-6694, DOI https://doi.org/10.2217/fon-2019-0143.
Full text not available from this repository.Abstract
Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg/day or placebo for 1 year after trastuzumab-based adjuvant therapy. Results: A total of 341 patients were from Asia (neratinib, n = 165; placebo, n = 176). 2-year invasive disease-free survival rates were 92.8 and 90.8% with neratinib and placebo, respectively (HR: 0.70; 95% CI: 0.31-1.55), and 5-year rates were 91.9 and 87.2%, respectively (HR: 0.57; 95% CI: 0.27-1.13). Diarrhea was the most common adverse event with neratinib. Conclusion: Extended adjuvant therapy with neratinib reduces disease recurrences in Asian women with HER2-positive breast cancer. Trial registration: Clinicaltrials.gov NCT00878709. © 2019 Future Medicine Ltd.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | Asia; early stage breast cancer; efficacy; extended adjuvant therapy; HER2; neratinib; safety; tyrosine kinase inhibitor |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 26 Mar 2020 04:50 |
| Last Modified: | 26 Mar 2020 04:50 |
| URI: | http://eprints.um.edu.my/id/eprint/24103 |
Actions (login required)
 |
View Item |
